FDANews
FDAnews Drug Daily Bulletin

Sanders, Cummings Launch Congressional Investigation into Marathon’s $89,000 Drug

Feb. 21, 2017

Two congressmen sent a letter to the CEO of Marathon Pharmaceuticals, calling the company’s decision to market an old drug for Duchenne muscular dystrophy for $89,000 per year  “outrageous” and “unconscionable.”

Sen. Bernie Sanders (I-Vt.) and Rep. Elijah Cummings (D-Md.) urged the company to significantly lower its price for Emflaza (deflazacort) — which had been previously available in Canada and the United Kingdom for years at an annual cost of about $1,000 — and said that they would launch an investigation.

View today's stories